Discover our extensive collection of research-grade antibodies,
rigorously validated for in vivo applications.
Precisely identify antibody-specific signals using matched isotype controls optimised for in vivo experimentation.
BiosimilarsInvestigate biological therapeutic mechanisms with cost-effective, research-grade biosimilar antibodies.
Jun 04, 2025
May 23, 2022
The InVivoPro Anti-Mouse PD-1(CD279) in vivo antibody, Clone 29F.1A12, has emerged as a cornerstone in preclinical immunotherapy research. Developed by BioXCell, this highly specialized monoclonal antibody targets murine PD-1, a key immune checkpoint
May 23, 2022
The InVivoPro Anti-Mouse CD8α in vivo antibody, Clone 2.43 has become a cornerstone in preclinical immunology research, offering researchers a precise and reliable tool to manipulate and study CD8⁺ T cells, the key cytotoxic effectors of the adaptive imm
May 23, 2022
The InVivoPro Anti-Mouse Ly6G in vivo antibody, Clone 1A8 has emerged as a crucial asset in preclinical research, offering a powerful means to study and manipulate neutrophil functions in various disease models. Ly6G, a cell surface antigen highly express
May 22, 2022
The InVivoPro Anti-Mouse CD4 in vivo antibody, Clone GK1.5 is a cornerstone tool in preclinical immunology research, enabling precise depletion of CD4⁺ T cells to study their role in immune responses. Developed by BioXCell, this monoclonal antibody target
May 22, 2022
The InVivoPro Anti-Mouse PD-L1 (B7-H1, CD274) in vivo antibody, Clone 10F.9G2 is a cutting-edge tool for preclinical cancer immunotherapy research, designed to block the PD-1/PD-L1 immune checkpoint pathway with high specificity and efficacy. Developed by
May 22, 2022
The InVivoPro Anti-Mouse PD-1 (CD279) in vivo antibody, Clone RMP1-14 has emerged as a pivotal tool in preclinical cancer immunotherapy research, enabling robust blockade of the PD-1/PD-L1 immune checkpoint pathway. This high-specificity monoclonal antibo
© 2021-2025 InvivoCrown Limited. All rights reserved.